All In Biotech

Drug Trial Radar · NCT07165951

Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

A Randomized, Double-blind, Parallel-controlled, Multicenter Phase III Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules to Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Last checked: Nov 20, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 566 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

566

Planned (sponsor's estimate)

Start

Dec 2, 2025

Primary completion

May 2028

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Sep 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study adopts a randomized, open label, placebo-controlled, multicenter trial design. OS was the primary endpoint, and eligible subjects were randomly divided into 1:1 groups and received TQB2868 injection and anlotinib hydrochloride capsules combined with chemotherapy, compared to placebo combined with chemotherapy.

Conditions

  • Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

  • TQB2868 InjectionDrug

    TQB2868 injection: PD-L1 and Transforming Growth Factor-beta (TGF - β) dual antibody

  • Anlotinib Hydrochloride CapsulesDrug

    Anlotinib Hydrochloride Capsules

  • Gemcitabine Hydrochloride InjectionDrug

    Gemcitabine Hydrochloride Injection

  • Paclitaxel for InjectionDrug

    Paclitaxel for Injection

  • TQB2868 PlaceboDrug

    TQB2868 Placebo without drug substance

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: The duration is approximately 2 years

Locations

71 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of USTC Anhui Provincial Hospital

    Hefei, Anhui, China · Not yet recruiting

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China · Not yet recruiting

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing Friendship Hospital,Capital Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • The Fifth Medical Center of Chinese People's Liberation Army General Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing Daxing District People'S Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Mengchao Hepatobiliary Hospital OF Fujian Medical University

    Fuzhou, Fujian, China · Not yet recruiting

  • The Firstaffiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Not yet recruiting

  • Zhongshan Hospital Xiamen University

    Xiamen, Fujian, China · Not yet recruiting

  • Gansu Provincial Hospital

    Lanzhou, Gansu, China · Not yet recruiting

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China · Not yet recruiting

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China · Not yet recruiting

  • Sun Yat-Sen University

    Guangzhou, Guangdong, China · Not yet recruiting

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Sun Yat-Sen University Cancer Center

    Guangzhou, Guangdong, China · Not yet recruiting

  • Longhua District Central Hospital

    Shenzhen, Guangdong, China · Not yet recruiting

  • Guangxi Cancer Institute

    Nanning, Guangxi, China · Not yet recruiting

  • Guizhou Medical University Affiliated Cancer Hospital Co., LTD

    Guiyang, Guizhou, China · Not yet recruiting

  • Affiliated Hospital of Zunyi Medical Universityl

    Zunyi, Guizhou, China · Not yet recruiting

  • Hainan general hospital

    Haikou, Hainan, China · Not yet recruiting

  • Cancer Hospital Chinese Academy pf Medical Sciences

    Langfang, Hebei, China · Not yet recruiting

  • Tangshan peopel's Hospital

    Tangshan, Hebei, China · Not yet recruiting

  • Daqing Oilfield General Hospital

    Daqing, Heilongjiang, China · Not yet recruiting

  • Harbin Medical University Cancer Hospital

    Haerbin, Heilongjiang, China · Not yet recruiting

  • The First Affiliated Hospital of Henan University of Science & Technology

    Luoyang, Henan, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Not yet recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Not yet recruiting

  • Hubei Cancer Hospital

    Wuhan, Hubei, China · Not yet recruiting

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • People's Hospital of Hunan Province

    Changsha, Hunan, China · Not yet recruiting

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

  • Peking University Cancer Hospital Inner Mongolia Hospital

    Hohhot, Inner Mongolia, China · Not yet recruiting

  • Jiangyin People'S Hospital

    Jiangyin, Jiangsu, China · Not yet recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • Nantong Tumor Hospital

    Nantong, Jiangsu, China · Not yet recruiting

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Not yet recruiting

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.